Page Title
Clinical Trial Finder
You can help advance cystic fibrosis research — starting now.
Tailor your search using the filters on the left.
Need help? Watch a video tutorial or contact the Clinical Trial Navigator, a real person who can assist you.
Showing 1-1 of 1 studies
Tailor your search using the filters on the left.
Need help? Watch a video tutorial or contact the Clinical Trial Navigator, a real person who can assist you.
Showing 1-1 of 1 studies
-
Restore CFTR ProteinClosed to Enrollment
Study of VX-828 in combination with Tezacaftor and Deutivacaftor in healthy participants and in adults with cystic fibrosis. , protocol number Vertex VX23-828-001 Phase 1 Part EPart E of this study will look at the safety and tolerability of VX-828 in combination with Tezacaftor and Deutivacaftor in adults with CF. The drug combination is intended to help CFTR function closer to normal.
-
Age:
18 Years and Older
-
Mutation(s):
One Copy F508del
-
FEV1% Predicted:
40% or greater
-
Number of Visits:
12
-
Length of Participation:
4 months
-
Showing 1-1 of 1 studies
- 1
Studies in this tool are multi-center studies facilitated by the Cystic Fibrosis Therapeutics Development Network. For a complete list of cystic fibrosis related studies, visit www.clinicaltrials.gov.
Related Topics
CONTACT THE CLINICAL TRIAL NAVIGATOR
Get personalized assistance and answers to your clinical trial questions.
Learn MoreSign up for clinical trial alerts
Get email updates about clinical trials that matter to you.
Check the Drug Development Pipeline
We’re attacking CF from every angle. Learn about the status of CF drugs in development.
Learn More